Tuesday, April 7, 2020
The Forum for Development and Human Rights Dialogue Foundation on Tuesday called on the World Health Organization (WHO) to monitor the announcement by the United States, China and the European Union to conduct clinical trials of a number of pharmaceuticals for the treatment of CORONA virus patients, the compatibility of research and medical intervention with basic standards of patient safety and the development of the guidelines for good clinical practices (GCP) in accordance with the Helsinki Declaration of 1964, and not to try any treatment or without sufficient evidence to confirm that there is no harm to the health of those who are undergoing the experiment within a set timeframe of research and not to repeat this trial if it fail, taking into account the prohibition of trials on pregnant women once and for all, as well as children under the age of 18, unless they are sick and research is related to their illness, and also permanently prohibit it on psychiatric patients, especially psychiatric hospital inmates. .
The Forum stressed the need for the United Nations and the World Health Organization to monitor any therapeutic research, and that these trials should not be conducted until the approval of the Health Authority/Committee for Scientific Research Ethics in the country where it requests approval for treatment from those authorities, and that the authorities are responsible for scrutinizing the expected benefits and potential risks of trials. However, this consent only gives authority to conduct the trial and does not mean that the treatment will be safe or effective.
These trials are performed only after obtaining the approval of the patient involved in the trial
and treat them as independent people themselves, and give them the right to withdraw from the research at any time, and the presence of academic honesty, and finally the expected benefits should be greater than the potential risk.